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Abstract
Autoimmune diseases are believed to be highly dependent on loss of immune tolerance to self-
antigens. Currently, no treatments have been successful clinically in inducing autoantigen-specific 
tolerance, including efforts to utilize antigen-specific immunotherapy (ASIT) to selectively correct 
the aberrant autoimmunity. Soluble antigen arrays (SAgAs) represent a novel autoantigen delivery 
system composed of a linear polymer, hyaluronic acid (HA), displaying multiple copies of 
conjugated autoantigen. We have previously reported that Soluble Antigen Arrays proteolipid 
protein (SAgAPLP) induced tolerance to a specific multiple sclerosis (MS) autoantigen, proteolipid 
peptide (PLP). Utilizing SAgA technology, we have developed a new ASIT as a possible type 1 
diabetes (T1D) therapeutic by conjugating human insulin to HA, known as Soluble Antigen Array 
Insulin (SAgAIns). Three types were synthesized: low valency lvSAgAIns (2 insulins per HA), 
medium valency mvSAgAIns (4 insulins per HA) and, high valency hvSAgAIns (9 insulins per HA) 
to determine if valency differentially modulates the ex vivo activity of insulin-binding B cells 
(IBCs). Extensive biophysical characterization was performed for the SAgA molecules. SAgAIns 
molecules were successfully used to affect the biologic activity of IBCs by inducing 
desensitization of the B cell antigen receptors (BCR). SAgAIns bound specifically to insulin-
*To whom correspondence should be addressed: University of Kansas, 2030 Becker Drive, Lawrence, KS 66047., Phone: (785) 
864-1455, Fax: (785) 864-1454, berkland@ku.edu.
†Co-first authors.
AUTHOR CONTRIBUTIONS
M.A.L. performed the synthesis, characterization, and biophysical analysis for the novel soluble antigen arrays and wrote the 
manuscript. S.M.W. performed the ex vivo cell assays, flow cytometry, data analysis, and wrote the manuscript. J.K.R. helped with 
synthesis and biophysical data analysis. N.L. and C.R.M. performed and interpreted data from biophysical analyses. J.C.C. and C.J.B. 
are the principal investigators. Finally, support for the NMR instrumentation was provided by NIH Shared Instrumentation Grant # 
S10RR024664 and NSF Major Research Instrumentation Award # 1625923
Supporting Information.




Mol Pharm. Author manuscript; available in PMC 2020 August 25.
Published in final edited form as:













reactive B cells without blocking epitopes recognized by antibodies against the Fc regions of 
membrane immunoglobulin or CD79 transducer components of the BCR. Pre-incubation of IBCs 
(125Tg) with SAgAIns, but not HA alone, rendered the IBCs refractory to re-stimulation. SAgAIns 
induced a decrease in BCR expression and IP3R-mediated intracellular calcium release. 
Surprisingly, SAgAIns binding to BCR on the surface of IBCs induced the observed effects at both 
high and low SAgAIns valency. Future studies aim to test the effects of SAgAIns on disease 
progression in the VH125.NOD mouse model of T1D.
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Autoimmune diseases; type 1 diabetes; Soluble Antigen Array; Insulin; B cell antigen receptors; 
tolerance; ex vivo; epitope; valency; anergized
INTRODUCTION
Autoimmune diseases, such as multiple sclerosis (MS),1, 2 type 1 diabetes (T1D),3–7 
neuromyelitis optica,8, 9 and lupus erythematosus,10, 11 involve loss of tolerance to self-
antigens in autoreactive B cells, leading to tissue damage, disability, and death. In 
individuals afflicted by T1D, the insulin-producing beta cells in the pancreas are targeted by 
an autoimmune response, resulting in cell death.3 While production of autoantibodies is a 
strong predictor of the development of T1D, no studies have shown such antibodies to be 
pathogenic. Instead, studies have suggested B cells may contribute to the development of 
disease via their antigen presenting function and/or cytokine production.3–7 Rituximab 
works by depleting B cells and has been used to treat certain autoimmune disease, including 
T1D. However, this monoclonal anti-CD20 antibody causes global B cell depletion, 
increasing risk of infection, and can exhibit limited efficacy.12–14 Antigen-specific immune 
therapy (ASIT) has emerged as a potential means to selectively induce immune tolerance,
15, 16 via an intervention similar to allergy shot therapies, which often use soluble antigens to 
restore tolerance towards specific allergens.17 Since B cells specificity is determined by cell 
surface antigen receptors, antigen-specific strategies to selectively tolerize or delete 
autoreactive B cells offer a promising approach to ASIT.
In now classic studies, Dintzis and co-workers analyzed the delivery of antigens bound to 
polymers, and reported two different antigen-specific responses dictated by the following 
properties: polymer molecular weight, solubility, and antigen valency and spacing. An 
immunogenic response was seen when polymers delivering haptens were large (>100 kDa), 
rigid, and poorly soluble. A tolerogenic effect occurred when polymers delivering haptens 
were smaller (<100 kDa), flexible, soluble, and often with relatively lower hapten density.
18–21 Interestingly, the molecular properties that encourage immune tolerance are also 
favorable for accessing B cell compartments in secondary lymphoid organs (<100 kDa)22, 23 
and may promote selectivity to antigen-specific B cells over other professional antigen 
presenting cells (pAPCs). We hypothesized that an antigen delivery system exhibiting 
molecular properties capable of inducing tolerance by engaging antigen-specific B cells may 
be a viable therapeutic for T1D.
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Our group has previously described a novel antigen delivery system known as Soluble 
Antigen Arrays (SAgAs), which were originally designed based on ‘Dintzis rules’. SAgAs 
are constructed using a hydrophilic linear polymer hyaluronic acid (HA) grafted with 
multiple repeating autoantigen. SAgA prototypes used proteolipid protein peptide 
(PLP139–151) to treat experimental autoimmune encephalomyelitis induced by this same 
peptide.24–32 SAgAPLP suppressed disease progression in many studies of this murine model 
used to mimic MS in humans. Our studies indicated SAgA engagement of B cell antigen 
receptors (BCRs) induced anergy, a known mechanism of peripheral immune tolerance. 
cSAgAPLP constructed via a non-hydrolyzable linker chemistry (i.e. covalent) rather than a 
hydrolyzable linker (SAgAPLP) showed greater binding in vitro to B cells and greater 
disease suppression in vivo.31, 32 In sum, SAgAs were able to target antigen-specific B cells, 
crosslink surface BCRs, and sustain receptor occupancy to effectively suppress autoreactive 
B cells.
We hypothesized that SAgAs composed of multiple human insulin molecules conjugated to 
HA may silence or delete B cells obtained from non-obese diabetic (NOD) mice transgenic 
for anti-insulin immunoglobulin heavy chain (VH125.NOD). Human insulin was conjugated 
onto HA using Copper-catalyzed Azide-Alkyne Cycloaddition (CuAAC) linker chemistry. 
Soluble Antigen Array Insulin (SAgAIns) products with different valency were synthesized 
(Scheme 1) and their biophysical properties were studied. Activity of SAgAIns was 
determined in B cells from both 125Tg (NOD) and VH125.NOD mice to confirm their 
ability to ligate BCR on the surface of insulin-specific B cells (IBCs). To further validate 
specificity, B cells (CD43-) purified from spleens of VH125.NOD mice and MD4 B cells 
(hen egg lysozyme (HEL) reactive) were mixed at approximately the same frequency as 
IBCs, thereby defining the ability of SAgAIns to selectively block binding of insulin to IBCs 
but not HEL binding to MD4 B cells. Lastly, to determine if SAgAIns can induce immune 
markers of anergy in IBCs, B cells from 125Tg mice were cultured in vitro with or without 
SAgAIns, or HA alone. These cells where subsequently assayed for surface levels of BCR as 
well as other markers to determine cell stimulation or anergy.
Experimental
Materials—Cell Prime™ r-insulin recombinant human insulin was purchased from EMD 
Millipore Corporation (Chicago, IL). N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC), 2-(N-morpholino)ethane-sulfonic acid sodium salt (MES), tris(3-
hydroxypropyltriazolylmethyl)amine, sodium ascorbate (NaAsc), and Propargyl-N-
hydroxysuccinimidyl ester were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
received without further purification. Hyaluronic acid (HA) sodium salt (MW 16 kDa) was 
purchased from Lifecore Biomedical (Chaska, MN). 11-azido-3,6,9-trioxaundecan-1-amine 
(NH2-PEG3-N3), N-hydroxysuccinimide, Copper (II) sulfate pentahydrate (CuSO4 • 5H2O) 
was purchased from Acros Organics (Geel, Belgium). Alkyne-functionalized peptide bearing 
an N-terminal 4-pentynoic acid (homopropargyl, hp) modification, hpPLP139–151 (hp-
HSLGKWLGHPDKF-OH) was originally synthesized in our laboratory via solid phase 
peptide synthesis. Larger quantities of hp PLP139–151 peptide was obtained from Biomatik 
USA, LLC (Wilmington, DE). VH125.NOD and MD4 mice were purchased from The 
Jackson Laboratory and 125Tg mice were a kind gift from the laboratory of Dr. Rachel 
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Friedman (National Jewish Health, Department of Biomedical Research). CD43 negative 
selections were purchased from Miltenyi Biotec and Millipore Sigma respectively. B76 and 
HM79 were produced in the Cambier laboratory and were directly conjugated to 
fluorochromes (Thermo Fisher Scientific). 5 uM Indo-1 acetoxymethyl calcium indicator 
were purchased from Molecular Probes. All other chemicals and reagents were analytical 
grade and used as received.
Synthesis and Labeling of Soluble Antigen Arrays—Soluble antigen arrays (SAgAs 
were synthesized and characterized as previously reported.31, 32 Protein conjugation was 
determined through gradient reverse-phase analytical high-performance liquid 
chromatography (RP-HPLC).
Synthesis of Alkyne-Functionalized Human Insulin (Ins-Alk)—Synthesis of Ins-
alk was adapted from Patent No.: US 8,906,850 B2. 120.00 mg of powdered human insulin 
is dissolved in 3000 μL of anhydrous DMSO at room temperature followed by the addition 
of 120 μL of triethylamine (TEA). The solution is stirred for 30 min at room temperature. 
Next, 1.2 equivalents of Propargyl-N-hydroxysuccinimidyl ester is slowly added to the 
insulin-TEA solution as a 1.0 M solution of the Propargyl-N-hydroxysuccinimidyl ester in 
THF. The reaction is mixed for 1h and then quenched via the addition of 9.7 μL of a stock 
solution containing 250 μL of ethanolamine in 5,000 μl of DMSO followed by mixing for 
five min. (37.8 mg, 30.51%); LCMS (TOF ESI+) expected [M]+: 5918.66, found: 5918.66.
Synthesis of Azide Functionalized Hyaluronic Acid (HA-N3)—Synthesis of HA-N3 
was adapted from Hu et al and Di Meo et al. Sodium hyaluronate (93.9 μmol, 16 kDa 
average MW) was added to a 250 mL round bottom flask with stir bar, followed by 100 mL 
of 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH = 4.0). The mixture was 
stirred until in solution (~15 min) before EDC (23.1 mmol) was added neat, then N-
hydroxysuccinimide (18.8 mmol) was added neat. The mixture was stirred for 5 min before 
H2N-PEG3-N3 (4.51 mmol) in 20 mL MES buffer was added. The solution was then stirred 
for 24 h at room temperature before being dialyzed in 6–8 kDa cutoff dialysis tubing against 
4.5 L of 1.0 M NaCl solution for 24 h, then 4.5 L of deionized water (4 × 12 hours). The 
volume in the bag was then transferred to vials, frozen, and lyophilized to yield a white 
powder (1.61 g, 95.0%).
Synthesis of SAgA Insulin (SAgAIns)—Three different reactions with 5 equivalents of 
Ins-Alk relative to HA-N3 (to make lvSAgAIns and mvSAgAIns) and 10 equivalents of Ins-
Alk relative to HA-N3 (hvSAgAIns) were set up with the following conditions. HA-N3 (0.81 
μmol) was added as a 15 μM solution in phosphate buffer (50 mM, pH= 7.0) to a 100 mL 
round bottom flask with stir bar. Followed by the addition of insulin-alkyne, a 4.0 mM or 8.1 
mM solution in DMF (5 and 10 equivalents relative to HA-N3 respectively) was also added. 
Then a premixed solution of THPTA (60 μmol) and CuSO4 • 5H2O (12 μmol) in phosphate 
buffer (50 mM, pH= 7.0) was added to the alkyne/azide mixture. Then a 100 μL aliquot was 
removed for HPLC analysis. NaAsc (242 μmol) was then added to the reaction mixture as a 
100 mM solution in phosphate buffer (pH= 7.0). One reaction with 5 equivalence of Ins-Alk 
relative to HA-N3 was stirred at room temperature for 24h until some alkyne component was 
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consumed to furnish lvSAgAIns. While two other reactions were stirred at elevated 
temperature (40°C) for 24 h until all alkyne component was consumed to produce both 
mvSAgAIns and hvSAgAIns. Additional 100 μL aliquots were removed throughout the course 
of the reaction to determine the extent of conjugation. Upon completion of the reaction, the 
solution was quenched by adding 0.5 mL of 50 mM EDTA, then transferred to 6–8 kDa 
dialysis tubing and dialyzed against 4.5 L of 1.0 M NaCl (3 × 8 hours), then 4.5 L of 
deionized H2O (6 × 8 hours). The volume in the bag was then transferred to vials, frozen, 
and lyophilized.
Analytical Characterization of Click Soluble Antigen Arrays—NMR spectra were 
collected on a Bruker Avance AVIII 500 MHz spectrometer equipped with a dual carbon/
proton cryoprobe (unless otherwise noted), and all samples were dissolved in 650 μL of D2O 
for analysis. MestReNova 11.0 was used for NMR data analysis. The amide methyl 
resonance (δ ~ 1.90–2.05 ppm) of all 1H NMR spectra was normalized to an integration of 
3.0, and the sum of all other signals in the range of δ ~ 1.0–4.0 ppm was used to 
ratiometrically determine the number of azide functionalization sites during HA-N3 
synthesis.
RP-HPLC and SEC analysis were conducted using a Waters Alliance HPLC system 
equipped with either a diode array detector or dual wavelength UV/Vis detector. For the 









where Ncon = number of conjugated peptides per backbone, npep = moles of peptide used in 
reaction, nHA = moles of HA-N3 used in reaction, Vpre = total reaction volume before 
NaAsc is added, Vsam = volume of “pre-NaAsc” sample removed from reaction mixture, PAt 
= measured peak area of peptide at time t, PAstart = measured peak area of free peptide 
before NaAsc is added to the reaction. General chromatographic conditions employed a 
Waters XBridge C4, 3.5 μm, 300 Å stationary phase under ion pairing (0.05% TFA in H2O 
and MeCN) mobile phase conditions, utilizing a linear elution gradient (5–70%) with 
detection at 214 nm.
Biophysical Characterization
Determination of protein concentrations was done with ε280 nm (3 mL⋅g−1⋅cm−1) for human 
insulin. For derivatized polymers, the concentrations were determined on a total protein 
basis (the same absorbance) so that the total concentration of insulin is unchanged. Other 
polymers and fluorescence concentrations were determined by weight.
Far UV Circular Dichroism—Far UV circular dichroism spectroscopy was perform using 
an Applied Photophysics Chirascan equipped with a 6-cell holder (Applied Photophysics, 
Leatherhead, UK).33 Proteins were at concentrations of ~0.1 mg/ml, in 10 mM phosphate 
Buffer pH 7.4 or pH 3.0, in a 1-mm quartz cell. CD was measured from 195 – 250 nm and 
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using a 1 nm step size with a two second integration time at each step. Corresponding 
buffers were subtracted for each sample.
Dynamic Light Scattering—Dynamic light scattering was performed using a DynaPro 
Plate Reader (Wyatt Technology, Santa Barbara, CA).34 Incident light was detected in a 
backscattering configuration and analyzed with an autocorrelator. Twenty μL of sample, in 
10 mM phosphate Buffer pH 7.4, was placed in a clear-bottomed 384 well plate and read at 
20°C. Samples were measured 5 times with a 15 second acquisition time. Autocorrelation 
functions were fit using cumulant analysis and intensity averaged values are reported. Errors 
are reported as standard deviation of 3 replicates.
Intrinsic Fluorescence Spectroscopy—Intrinsic fluorescence was measured as 
described previously using custom fluorescence plate reader (Fluorescence Innovations, 
Minneapolis, MN).34 Briefly, a 285 nm laser was used to excite samples and fluorescence 
was collected at 180° after passing through a 310 nm longpass filter to block excitation light. 
A prism dispersed light onto a CCD to quantify the fluorescence as a function of 
wavelength. 10 μL of sample, in 10 mM phosphate Buffer pH 7.4, was placed in a 384 well 
plate and covered with 2 μL of silicon oil to prevent sample evaporation. The fluorescence 
was measured from 10 to 90°C with a step-size of 1.25°C and an equilibration step of 2 min 
between each temperature. The total intensity from 300 to 400 nm was averaged for each 
temperature. Error bars represent the standard deviation of 4 replicates.
Mice—Female mice, aged 6–8 weeks, were used in all experiments. VH125.NOD mice 
express, by virtue of knock-in, the variable heavy-chain region from the insulin specific 125 
hybridoma, on the NOD background. Together with endogenous light chains, these mice 
bear ~3 % insulin reactive B cells in the periphery. 125Tg mice express both the heavy- and 
light-chain from the 125 hybridoma, rendering 100 % of their peripheral B cells reactive to 
insulin. MD4 mice express both a heavy- and light-chain specific for hen-egg lysozyme 
(HEL); the sole antigen specificity of all B cells in this mouse. Mice were housed and bred 
at the University of Colorado Denver Anschutz Medical Campus Vivarium or in the 
Biological Resource Center at National Jewish Health. All experiments involving mice were 
performed in accordance with the regulations and with approval of the University of 
Colorado Denver Institutional Animal Care and Use Committee and National Jewish Health.
Tissue harvest—Spleens were harvested in IMDM supplemented with 5 % FCS, 1 mM 
sodium pyruvate, 50 ug/mL gentamicin, 100 U/mL penn/strep, 2 mM L-glutamine, and 5E-5 
M beta-mercaptoethanol; single cell suspensions were prepared by mechanical disruption. 
RBC’s were lysed with 1mL ACK (150 mM NH4Cl, 10 mM KHCO3, 100 mM Na2EDTA) 
for 1 min at room temperature (RT). Cells were subsequently washed and resuspended in 
either complete medium containing 0.1 % NaN3 or complete medium alone for staining or 
calcium measurement, respectively. For staining of VH125.NOD + MD4 B cells, B cells 
were purified via CD43 negative selection before mixing MD4 B cells (~1%) into the 
VH125.NOD B cells.
Flow cytometry—Cells were resuspended at 1E7 cells/mL in cold complete medium 
containing 0.1 % sodium azide (NaN3). 100 μL aliquots containing 1E6 cells were stained 
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with fluorescently-conjugated monoclonal antibodies. Antibodies against the following cell-
surface molecules were used: B220 (RA3–6B2; BD), IgM-AF488 (B76) and, CD79b-PE 
(fab; HM79). B76 and HM79 were produced in the Cambier laboratory and were directly 
conjugated to fluorochromes according to the manufacture’s protocol. For the detection of B 
cells expressing insulin reactive B cell receptors, cells were first incubated with or without 
SAgAIns molecules or hyaluronic acid (HA) alone [0.5 ug] for 20 min at 4 degrees C. After 
two washes and resuspension in 100 μL medium, cells were stained with monomeric 
biotinylated insulin (ins-bt) (1:50), and HEL-AF488 (1:200) for VH125.NOD + MD4 
experiment, for 20 min at 4°C. Cells were washed again before adding anti-B220 (APC, PE, 
or BUV396), anti-IgM, fab anti-CD79b and, fab anti-biotin-AF647. Following final 
incubation and washing, cells were analyzed on a Fortessa X-20 flow cytometer (BD) and 
analyzed using FlowJo software (Tree Star).
Calcium mobilization—For measurements of relative intracellular free calcium 
concentration ([Ca2+]i), 125Tg RBC-lysed splenocytes (1E7/ mL in complete medium 
containing 2 % FCS) were incubated with or without SAgAIns or HA, for 4 h at 37°C and 5 
% CO2. For an additional hour at RT, cells were simultaneously stained with anti-B220-APC 
(1:500), fab anti-CD79b-PE (1:500) and, loaded with 5 uM Indo-1 acetoxymethyl. After 
washing once in medium, cells were resuspended at 5E6 cells/ mL in RT medium in 500 μL 
aliquots. Indo-1 was excited with a 355-nm UV laser, Ca2+ -bound Indo-1 was detected with 
a 379/28 bandpass filter; unbound Indo-1 was detected with a 524/40 bandpass filter. 
Relative free intracellular calcium concentration was determined by calculating the ratio of 
bound/unbound Indo-1. After acquiring data for 30 s, to establish a baseline, cells were 
stimulated with the indicated dose of SAgAIns molecules, anti-IgM [B76] and/or ionomycin 
and data collected for an additional 2 min 30 sec. Relative mean [Ca2+]i was measured on a 
Fortessa X-20 flow cytometer and analyzed with FlowJo software.
Statistical Analysis—GraphPad Prism was used to perform statistical analysis including 
sigmoidal nonlinear regression, ordinary one-way or two-way analysis of variance 
(ANOVA), and unpaired t-test. ANOVA was followed by Tukey’s or Sidak’s post-hoc test, 
where appropriate. The threshold for statistical significance was set to p<0.05.
RESULTS AND DISCUSSION
Structural Design of Click Soluble Antigen Arrays
SAgAs were synthesized by conjugating multiple modified autoantigen (human insulin 
alkyne; Ins-alk) molecules to 16 kDa hyaluronic acid (HA) to produce the following 
conjugates: low valency (2 insulin per HA; lvSAgAIns), medium valency (4 insulin per HA; 
mvSAgAIns) and, high valency (9 insulin per HA; hvSAgAIns). SAgAs are designed to 
diffuse from the injection site and drain into secondary lymphoid organs to access B cells 
and other immune cells. Dintizis’ reported antigen structural properties that induce tolerance 
in B cells and provide a useful design framework: <100 kDa, flexible, and highly soluble. 
We hypothesized that SAgAs with >5 insulin molecule per HA would induce anergy in 
insulin-specific B cells (IBCs).
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Synthesis and Analytical Characterization of Click Soluble Antigen Arrays
Both qualitative and quantitative analytical techniques were used to characterize SAgAs and 
their components. The amine pegylated azide (H2N-PEG3-N3) was conjugated to HA via (1-
Ethyl-3-(3-dimethylaminopropyl)-carbodiimide)/N-hydroxysuccinimide (EDC/NHS) 
coupling chemistry. 1H NMR was used to quantify azide functionalization of HA-azide 
revealing an average of 41 azides per HA (Figure 1). This was done by integrating a peak 
from the HA backbone, highlighted in yellow (Figure 1B; (δ(1H) ≈ 2.0 ppm), and a peak in 
HA-azide (HA-N3) that corresponds to a methylene peak, highlighted in blue (Figure 1A; 
(δ(1H) ≈ 2.5 ppm). Resonance peaks δ(1H) ≈ 2.7 ppm or 2.9 ppm in Figure 1B correspond 
to methylene protons in the linker can also be used to determine conjugation efficiency. Due 
to manual integration performed to determine conjugation and the heterogeneity of HA, this 
analysis should be considered semiquantitative. Modification of the autoantigen human 
insulin was conducted by conjugating an alkyne linker (Propargyl-N-hydroxysuccinimidyl 
ester) via NHS chemistry to furnish insulin-alkyne (Ins-Alk). LC-MS verified the successful 
synthesis of Ins-Alk and further characterization of the modified protein led to the 
identification of the site of modification. LC/MS analysis determined that two species of Ins-
Alk existed. Either B29 lysine was modified or modification occurred on the N-terminus on 
the A chain (Figure S1A; S1B), either site being acceptable for retaining accessibility of the 
bulk of the insulin structure.
CuAAC reaction conditions were used to conjugate Ins-alk to HA-N3 to produce prototype 
low valency lvSAgAIns (2 Ins per HA). Next, medium valency mvSAgAIns (4 Ins per HA) 
and high valency hvSAgAIns (9 Ins per HA) were analyzed by reverse-phase analytical high-
performance liquid chromatography (RP-HPLC) to determine the molecular weight and 
protein conjugation (Figure S2; See Equation 1). The complete conjugation of Ins-Alk to 
HA-N3 for mvSAgAIns and hvSAgAIns can be seen in both Figure S2A and Figure S2B. It 
should be noted that two aliquots from each reaction were taken before Sodium Ascorbate 
(NaAsc) was added. One aliquot was used to determine total Ins-Alk in solution and the 
second was analyzed under the same conditions as the reaction mixture without NaAsc to 
determine protein degradation over 24h (~1 Ins-Alk).
1H/13C Heteronuclear Single Quantum Coherence (HSQC) NMR spectroscopy was used to 
qualitatively confirm the homopropargyl linker on the Ins-Alk (green resonance; δ(1H) ≈ 2.9 
ppm, δ(13C) ≈ 70 ppm; Figure 2A, 2C). When both human insulin (red resonance) and Ins-
Alk (green resonance) HSQC spectra were superimposed, some residue resonance signals 
pointed towards little to no structural change (Figure 2B, 2D; black square), while distinct 
conformational differences were predominately seen in the aromatic region for Ins-Alk 
(Figure 2B; black circles). These differences suggested the installation of the homopropargyl 
handle caused a buried aromatic amino acid (i.e. phenylalanine) to become solvent exposed, 
thus becoming detectable by NMR. Finally, HSQC analysis revealed the absence of the 
unique resonance signal for the homopropargyl linker on Ins-Alk (δ(1H) ≈ 2.9 ppm, δ(13C) 
≈ 70 ppm; black triangle) in both the mvSAgAIns and hvSAgAIns spectrum (Figure 2E and 
2F), thus confirming the final products contained only the conjugated protein.
Circular Dichroism (CD) analysis of human insulin was consistent with previously reported 
alpha helical secondary structure (Figure 3A, 3B). SAgAIns mostly retained alpha helical 
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secondary structure in both neutral (pH 7.4) and acid media (pH 3.0), however, hvSAgAIns 
appeared to lose significant secondary structure under acidic conditions (Figure 3A, 3B). 
Further analysis of CD data revealed greater loss of alpha helical structure for hvSAgAIns 
when compared to mvSAgAIns in both acidic and neutral solutions (Figure 3A, 3B). When 
directly studying the effect of pH on each SAgAs, secondary structure was compromised at 
lower pH when compared to neutral conditions. HSQC NMR analysis in combination with 
CD data may explain the loss of secondary structure of SAgAIns when compared to native 
human insulin. Alkyne modification resulted in a physical change in protein structure that 
permitted hydrophobic residues to be detected using HSQC NMR. These hydrophobic 
resides such as tyrosine may interfere with a lpha helical structure. In addition, acidic amino 
acids (i.e. aspartic acid and glutamic acid) become more protonated at lower pH, which may 
disrupt salt bridges which could alter the peptide secondary structure.
Melting of the secondary structure as monitored by CD (Figure 3C) shows a minor transition 
in the insulin secondary structure (Tm ~55°C) which is substantially reduced when the 
protein is conjugated to HA. A temperature melt plot based on intrinsic fluorescence (Figure 
3D) showed only weak evidence of the transition for insulin alone with the modified forms 
manifesting its absence. This may be explained by the fact that insulin contains three 
disulfide bonds which strongly stabilize the protein. The loss of the transition in the 
conjugated form suggest some further stabilization of the protein. Finally, dynamic light 
scattering showed a significant size increase for the conjugated forms (Table 1). A large 
increase in size for hvSAgAIns may correlate with the partial loss in alpha helical structure 
(Figure 3), where the SAgAIns would now favor more extended forms as well as 
intermolecular interactions that may lead to self-association.
SAgAIns binding and effects on ex vivo IBCs
Insulin-SAgAs bind specifically to insulin reactive B cells—To assess the 
immunological effects of multimeric, insulin-polymer (SAgAIns) molecules, we first 
determined if SAgAIns are capable of ligating B cell receptors (BCR) on the surface of IBCs. 
To this end, we utilized B cells from 125Tg mice in which, by virtue of heavy- and light-
chain knock-in, harbor peripheral B cells with an insulin reactivity-fixed receptor repertoire. 
Red blood cell (RBC)-lysed, 125Tg splenocytes were first incubated with or without 
SAgAIns (low or high avidity) or hyaluronic acid (HA) alone for 20 min, at 4 °C, in 
complete medium containing 0.1 % NaN3. Staining under these conditions prevents the 
internalization of ligated BCR. After being washed, cells were exposed to monomeric 
biotinylated insulin (ins-bt), washed, and subsequently stained with antibodies against B220 
(B cells), CD79b (BCR) and, immunoglobulin (IgM, BCR) together with anti-biotin. 
Depicted in Figure 4A, pre-treatment with SAgAIns, but not HA alone, blocked binding of 
ins-bt. Staining in which ins-bt was omitted served as a positive control and staining with no 
SAgAIns pre-treatment served as a negative control. In addition, neither SAgAIns nor ins-bt 
bound to non- (B220-) B cells (data not shown). In anticipation of experiments in which we 
re-stimulate SAgAIns tolerized IBCs, we wanted to ensure that SAgAIns binding to the BCR 
did not obscure binding of BCR stimulating antibodies. In this case, cells previously 
exposed to the SAgAIns where subsequently stained with anti-IgM [B76] and anti-CD79b 
[HM79]. No change in staining intensity was detected for anti-BCR antibodies in cells 
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pretreated with SAgAIns (Figure 4B). Finally, to address SAgAIns binding in a more 
physiologic, clonally diverse setting, we utilized B cells (CD43-) purified from spleens of 
VH125.NOD mice in which ~1–3% of peripheral B cells bind insulin. To ensure specificity, 
MD4 B cells (HEL reactive) were mixed in at approximately the same frequency as IBCs. 
As before, cells were pretreated with SAgAIns or HA alone before being stained with ins-
bt/fab anti-bt-AF647 and HEL-AF488. As displayed in Figure 4C, SAgAIns blocked binding 
of ins-bt but not HEL-AF488.
In vitro incubation of IBCs with insulin-SAgA leads to decreased expression 
of BCR and desensitization of the BCR to additional stimulation—SAgAIns are 
designed as potential therapeutic agents for preventing the development of T1D. B cells are 
required for the development of T1D in mice and have been strongly implicated in human 
disease, probably functioning as antigen presenting cells needed for T cell activation in the 
pancreas.35 Depletion of B cells with an anti-CD20 antibody (rituximab) has been shown to 
delay the progression of disease in humans.36 Similarly, tolerization of peripheral B cells by 
chronic BCR stimulation has been observed to delay disease onset in mice.37 Following 
from this, we hypothesized that tolerizing antigen-(insulin) specific B cells may prove to be 
similarly efficacious in preventing T1D progression. Antigen specific tolerization comes 
with the added benefit of allowing the remainder of the B cell compartment to remain active 
for fighting infection and responding to vaccination.
To determine if SAgAIns are capable of tolerizing IBCs, we again utilized B cells from the 
125Tg mouse. We first measured intracellular calcium mobilization in response to acute 
stimulation with SAgAIns (Figure 5A). Anti-IgM and HA alone were used as positive and 
negative controls, respectively. SAgAIns stimulated a similar calcium flux in comparison to 
stimulation with anti-IgM (note that 125Tg B cells exclusively express IgM). Next, we 
incubated 125Tg IBCs with or without SAgAIns or HA alone for ~5 h before measuring 
surface BCR expression and calcium mobilization (Figure 5B, 5C). Pre-incubation with 
SAgAIns led to decreased expression of surface BCR, as measured by CD79b, reminiscent of 
chronically stimulated, anergic B cells found in mice and humans (Figure 5B).35 Pre-
incubation with SAgAIns, but not HA, rendered IBC’s refractory to re-stimulation through 
the BCR (Figure 5C). This inhibition was not due to masking of the epitope on the BCR 
recognized by B76 (Figure 5B) and was independent of the SAgAIns induced decrease in 
surface BCR (gating in Figure 5B). In addition, cells incubated with SAgAIns remained 
refractory to a 5-fold excess of anti-IgM stimulation (Figure 5C dashed lines), which as 
expected increased calcium response in untreated or HA treated cells (Figure 5A, 5C). 
Finally, SAgAIns induced desensitization of the BCR is independent of Inositol trisphosphate 
receptor (IP3) receptor-mediated release of intercellular calcium stores, since stimulation 
with the calcium ionophore, ionomycin, resulted in similar calcium influx in SAgAIns 
treated, HA treated, and untreated cells. This suggests that SAgAIns-induced tolerance of 
IBCs may rely on mechanisms observed to be operative in anergic B cells found in mice and 
humans.38
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SAgAs were successfully synthesized by conjugating multiple modified autoantigen human 
insulin (Ins-alk) molecules to the 16 kDa linear polymer hyaluronic acid (HA) to produce 
the following conjugates: low valency lvSAgAIns (2 insulin per HA), medium valency 
mvSAgAIns (4 insulin per HA)and, high valency hvSAgAIns (9 insulin per HA). Insulin 
conjugated to SAgAIns maintained alpha helical structure at physiological pH. Different 
valency SAgAIns did not appear to modulate biologic activity, producing similar levels of 
receptor blockade and BCR desensitization. SAgAIns bound specifically to IBCs without 
blocking epitopes recognized by antibodies against the BCR. The inability of SAgAIns-
treated IBCs to respond to BCR stimulation could potentially be explained simply by 
blocking of BCR epitopes recognized by the stimulating antibodies. Thus, the mechanism 
was more deeply assessed. Pre-incubation of IBCs (125Tg) with SAgAIns, but not HA, 
rendered the BCR desensitized to re-stimulation. This effect was independent of SAgAIns 
induced decrease in BCR expression and was also independent of IP3R-mediated 
intracellular calcium release. Activity was dependent on SAgAIns binding to BCR on the 
surface of IBCs and its ability to acutely stimulate these cells. SAgAIns silenced IBCs by 
inducing refractory B cell receptor signaling resulting in a mechanism of immune tolerance 
similar to B cell anergy, thus mimicking a known mechanism of peripheral tolerance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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1H NMR spectra of hyaluronic acid (HA) and hyaluronic acid azide (HA-N3). Peaks used to 
determine the average number of azides in HA-N3 are highlighted in yellow and blue.
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Overlapped HSQC NMR spectra of insulin (red resonance) and insulin alkyne (green 
resonance) (A-D). Multivalent SAgAs (mvSAgAIns) E and (hvSAgAIns) F show no 
resonances from the alkyne peak found only Ins-Alk present in either of the final 
compounds. The alkyne peak found in Ins-Alk is not found in any of the products, which 
implies no residual unconjugated insulin. HSQC NMR of A uses a black triangle to 
highlight the terminal alkyne proton in Ins-Alk. B shows more available aromatic residues in 
Ins-alk (green) when compared to insulin. C and D highlight similarities (black squares) and 
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differences (black circles) between insulin alkyne (green resonance) and insulin (red 
resonance).
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Far-UV Circular Dichroism of (A): mvSAgAIns and hvSAgAIns in phosphate buffer pH 7.4; 
(B): mvSAgAIns and hvSAgAIns in water pH 3.0; (C): medium and high valency SAgAs 
phosphate pH 7.4 temperature melt; (D): Intrinsic fluorescent temperature melt of SAgAs in 
phosphate pH 7.4.
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Specific binding of SAgAIns to insulin binding cells (IBCs). Both low-avidity (lvSAgAIns) 
and high-avidity (hvSAgAIns) molecules, but not hyaluronic acid (HA) alone, block binding 
of monomeric biotinylated-insulin to insulin-specific (B220+;125Tg) B cells (A.). 
Pretreatment of 125Tg B cells with either SAgAIns or hyaluronic acid does not block 
epitopes recognized by anti-IgM [B76] nor anti-CD79b [HM79] (B.). SAgAIns molecules 
block binding of insulin-bt to insulin specific B cells (CD43-, B220+;VH125.NOD) but not 
binding of hen egg lysozyme (HEL) to HEL specific B cells (CD43-, B220+;MD4) when 
both cell types are present at similar frequencies (C.). Layout gate frequencies represent 
percent of B cells (B220+). Data are representative of at least 3 independent experiments.
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SAgAIns effects on ex-vivo, insulin-binding cells (IBCs). SAgAIns molecules, but not 
hyaluronic acid (HA) alone, are capable of aggregating B cell receptors (BCR) on insulin 
specific B cells (125Tg) and stimulating extracellular calcium influx (A.). 5 hour pre-
incubation of IBCs (125Tg) with SAgAIns, but not HA, leads to decreased expression of 
BCR on the surface of IBCs (B.). Pre-incubation with SAgAIns renders IBCs refractory to 
re-stimulation through the BCR by anti-IgM [B76] but not to stimulation with the calcium 
ionophore, ionomycin (io) (C.). This induced tolerance is independent of the surface 
expression of BCR (gating in B.). Dashed calcium traces represent AgAIns treated (C.) or 
untreated (A.) cells stimulated with a 5-fold excess [25 ug] of anti-IgM . Data are 
representative of at least 3 independent experiments.
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(A): Synthesis of modified human insulin alkyne; (B) General synthesis of SAgAIns
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Table 1.
Insulin molar conjugation, as determined by RP- HPLC
a
. Dynamic light scattering (DLS) of SAgAs and 
components.






5.81 0 2.09 ± 0.02 8.00
24.50 0 6.5 ± 0.03 24.50
36.34 2 ---------- ----------
48.17 4 14.07 ± 0.63 26.55
77.76 9 14.07 ± 0.15 24.52
a
Results are an average of triplicate injections from a single batch preparation.
b
Calculated from RP-HPLC data. MW, molecular weight.
c
Insulin per HA, hyaluronic acid
d
DLS data were collected in triplicate
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